Constadina Arvanitis, Ph.D. - Publications

Affiliations: 
2008 Stanford University, Palo Alto, CA 
Area:
Oncology

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Eckerdt F, Alvarez A, Bell J, Arvanitis C, Iqbal A, Arslan AD, Hu B, Cheng SY, Goldman S, Platanias LC. A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. Biotechniques. 60: 43-6. PMID 26757811 DOI: 10.2144/000114372  1
2014 Arvanitis C, Khuon S, Spann R, Ridge KM, Chew TL. Structure and biomechanics of the endothelial transcellular circumferential invasion array in tumor invasion Plos One. 9. PMID 24587014 DOI: 10.1371/Journal.Pone.0089758  1
2010 Pichot CS, Arvanitis C, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-WASp. Cancer Research. 70: 8347-56. PMID 20940394 DOI: 10.1158/0008-5472.Can-09-4149  1
2009 Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, Corey SJ. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. British Journal of Cancer. 101: 38-47. PMID 19513066 DOI: 10.1038/Sj.Bjc.6605101  1
2008 Arvanitis C, Bendapudi PK, Tseng JR, Gambhir SS, Felsher DW. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biology & Therapy. 7: 1947-51. PMID 18981708 DOI: 10.4161/Cbt.7.12.6947  1
2008 Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. Plos Genetics. 4: e1000090. PMID 18535662 DOI: 10.1371/Journal.Pgen.1000090  1
2007 Arvanitis C, Bendapudi PK, Bachireddy P, Felsher DW. Identifying critical signaling molecules for the treatment of cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 172: 5-24. PMID 17607933 DOI: 10.1007/978-3-540-31209-3_2  1
2006 Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Seminars in Cancer Biology. 16: 313-7. PMID 16935001 DOI: 10.1016/J.Semcancer.2006.07.012  1
2005 Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Letters. 226: 95-9. PMID 16039948 DOI: 10.1016/J.Canlet.2004.10.043  1
2004 Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 431: 1112-7. PMID 15475948 DOI: 10.1038/Nature03043  1
2004 Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, Arvanitis C, Attardi LD, Feng S, Ruebner B, Cardiff RD, Felsher DW. Developmental context determines latency of MYC-induced tumorigenesis Plos Biology. 2. PMID 15455033 DOI: 10.1371/Journal.Pbio.0020332  1
2002 Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (New York, N.Y.). 297: 102-4. PMID 12098700 DOI: 10.1126/Science.1071489  1
Show low-probability matches.